One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair ...

How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical ...

The pivotal trial for Neurogene's Rett syndrome gene therapy makes use of baseline controls and a rigorous endpoint that ...

So, what were the major themes to come out of BIO Boston 2025? Who’s getting excited about what? And – besides the obvious ...

Nuravax Inc., a clinical-stage biopharmaceutical company developing active immunotherapies for neurodegenerative diseases, announced today that two oral presentations—the Phase 1 clinical results and ...

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of type-1 diabetes, hepatitis, ...

The partners will use UNP's AI-based macrocycle discovery platform to develop synthetic peptide therapeutics for multiple disease targets.

Cue Biopharma has received positive feedback from the Food and Drug Administration for its first in-human trial design for CUE-401, a protein that aims to treat autoimmune disease. The ...

Explore innovative clinical trial design with digital twins, enhancing predictions while reducing costs and efforts in ...

Sanaregen Vision Therapeutics invites investors to reserve shares as it prepares for an equity crowdfunding campaign to ...